Clinical trial finds heart-protective benefits for resveratrol
Tuesday, May 1, 2012. The results of a randomized trial published online on April 19, 2012 in The American Journal of Cardiology reveal a benefit for resveratrol in reducing cardiovascular disease risk factors in men and women taking statin drugs. “We have carried out the longest human trial reported thus far using a resveratrol-containing product,” announce researchers Juan Carlos Espín, PhD and his associates at CEBAS-CSIC and Morales Meseguer University Hospital in Murcia, Spain.
Dr Espin’s team divided 74 participants who were at high risk of cardiovascular disease to receive a grape extract containing 8 milligrams resveratrol, a grape supplement without resveratrol or a placebo daily for six months, followed by a six month period during which the dose of the treatments was doubled. Blood samples collected at the beginning of the study and at six and twelve months were analyzed for clotting factors, markers of inflammation and other values.
While the pro-inflammatory cytokine interleukin-6 increased and the anti-inflammatory molecule interleukin-10 had decreased by the end of the study in the placebo group, no changes were observed among those who received grape extract without resveratrol. Subjects who received resveratrol experienced a 1.3 milligram per liter average decrease in high-sensitivity C-reactive protein (hs-CRP) as well as a decline in tumor necrosis factor-alpha (TNF-a) by the end of twelve months, indicating a significant decrease in inflammation. Additionally, plasminogen activator inhibitor type 1 (PAI-1) was reduced, reflecting a reduction in the risk of excessive blood clotting, while adiponectin and interleukin 10 were increased in the group that received grape extract with resveratrol.
“In the present study, we describe for the first time that a dietary intervention with a specific grape nutraceutical containing resveratrol 8 milligrams significantly improved the inflammatory and fibrinolytic status of patients undergoing primary prevention of cardiovascular disease,” the authors write. “This resveratrol-rich grape supplement seemed to exert a statin-like effect beyond patients’ standard medication. In this regard, a synergistic effect between statins and this grape nutraceutical cannot be ruled out.”
“Our results show for the first time that a dietary intervention with grape resveratrol could complement the gold standard therapy in the primary prevention of cardiovascular disease,” they conclude.
Original article HERE